Evaluation of Renal Safety Between Imipenem/Relebactam and Colistin Plus Imipenem in Patients With Imipenem-Nonsusceptible Bacterial Infections in the Randomized, Phase 3 RESTORE-IMI 1 Study | Zendy

Michelle Brown | Zendy; J. Motsch | Zendy; Keith S. Kaye | Zendy; Thomas M. File | Zendy; Helen W. Boucher | Zendy; Neika Vendetti | Zendy; Angela Aggrey | Zendy; HeeKoung Joeng | Zendy; Robert Tipping | Zendy; Jiejun Du | Zendy; Daryl D. DePestel | Zendy; Joan R. Butterton | Zendy; Amanda Paschke | Zendy

Open Access

Evaluation of Renal Safety Between Imipenem/Relebactam and Colistin Plus Imipenem in Patients With Imipenem-Nonsusceptible Bacterial Infections in the Randomized, Phase 3 RESTORE-IMI 1 Study

Author(s) -

Michelle Brown,

J. Motsch,

Keith S. Kaye,

Thomas M. File,

Helen W. Boucher,

Neika Vendetti,

Angela Aggrey,

HeeKoung Joeng,

Robert Tipping,

Jiejun Du,

Daryl D. DePestel,

Joan R. Butterton,

Amanda Paschke

Publication year - 2020

Publication title -

open forum infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.546

H-Index - 35

ISSN - 2328-8957

DOI - 10.1093/ofid/ofaa054

Subject(s) - medicine , colistin , nephrotoxicity , acute kidney injury , kidney disease , rifle , adverse effect , imipenem/cilastatin , imipenem , cilastatin , gastroenterology , kidney , antibiotics , microbiology and biotechnology , antibiotic resistance , history , archaeology , biology

NCT02452047.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research